With new acquisition, Bora to venture into biologics
Last week, Taiwan-based CDMO Bora Pharmaceuticals announced that it acquired Eden Biologics. Now, it says that purchase has helped established Bora Biologics, expanding into the biopharmaceutical market.
The acquisition of the company’s assets, which are located in the Hsinchu Biomedical Science Park in Taiwan, is helping Bora build its presence in the biopharma world by expanding production capacity of cell lines for the production of protein drugs. It will also improve the quality control and inspection specifications, as well as cell bank generation. The facility has four 500-liter bioreactors that have been approved by European and Taiwanese regulators.
“The addition of the CDMO facilities equipment and the expertise of the highly qualified team gives Bora Biologics the ability to develop and continue with our clients as they progress to commercialization,” Bora VP Simon Chen said in a statement.
Taishin Healthcare Partnership and Allen Chao, the founder of Tanvex BioPharma, are both investors in Bora Biologics.
On May 10, Evofem Biosciences announced that it would enlist Bora Canada to manufacture Evofem’s drug Phexxi for markets across the world. Evofem will get a 45% cut on the cost of goods, through sending manufacturing, testing and packaging to Bora. Phexxi, a hormone-free contraceptive, was approved in 2020, and continues to grow in popularity for the use of preventing pregnancy in the US. The gel is used up to an hour before sex. Its ad campaign features “Schitt’s Creek” star Annie Murphy.